Metformin Use Is Associated With Longer Progression-Free Survival of Patients With Diabetes and Pancreatic Neuroendocrine Tumors Receiving Everolimus and/or Somatostatin Analogues.
暂无分享,去创建一个
V. Mazzaferro | S. Ricci | F. di Costanzo | L. Antonuzzo | S. Garattini | S. Cingarlini | M. Davi’ | A. Faggiano | A. Colao | F. Spada | N. Fazio | G. delle Fave | A. La Salvia | M. Brizzi | R. Berardi | A. Zaniboni | M. Di Maio | M. Milione | D. Giuffrida | L. Giacomelli | C. Carnaghi | G. Lo Russo | F. de Braud | V. Perfetti | S. Tafuto | T. Ibrahim | D. Campana | P. Ermacora | S. Massironi | E. Bajetta | A. Fontana | S. Pusceddu | R. Buzzoni | P. Razzore | N. Prinzi | C. Vernieri | M. Torniai | Alberto Bongiovanni | C. De Divitiis | F. Cavalcoli | Daniela Femia | F. Panzuto | M. Rinzivillo | R. Marconcini | N. Brighi | S. Ortolani | F. Aroldi | L. Catena | M. Duro | L. Concas | C. Cauchi | I. Puliafito
[1] B. Poch,et al. New Onset of Diabetes and Pancreatic Exocrine Insufficiency After Pancreaticoduodenectomy for Benign and Malignant Tumors: A Systematic Review and Meta-analysis of Long-term Results , 2018, Annals of surgery.
[2] R. Lloyd,et al. WHO classification of tumours of endocrine organs , 2017 .
[3] S. Freedman,et al. Impact of Treatments on Diabetic Control and Gastrointestinal Symptoms After Total Pancreatectomy , 2017, Pancreas.
[4] L. Harris,et al. Impact of Diabetes, Insulin, and Metformin Use on the Outcome of Patients With Human Epidermal Growth Factor Receptor 2-Positive Primary Breast Cancer: Analysis From the ALTTO Phase III Randomized Trial. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] Li Song,et al. Metformin Improves Overall Survival of Colorectal Cancer Patients with Diabetes: A Meta-Analysis , 2017, Journal of diabetes research.
[6] J. Berlin,et al. Phase 3 Trial of 177Lu‐Dotatate for Midgut Neuroendocrine Tumors , 2017, The New England journal of medicine.
[7] F. D. De Braud,et al. Targeting Cancer Metabolism: Dietary and Pharmacologic Interventions. , 2016, Cancer discovery.
[8] W. Lou,et al. Glucagonoma syndrome: report of one case. , 2016, Translational gastroenterology and hepatology.
[9] V. Mazzaferro,et al. Metformin with everolimus and octreotide in pancreatic neuroendocrine tumor patients with diabetes. , 2016, Future oncology.
[10] B. Vergès,et al. mTOR inhibitors and diabetes. , 2015, Diabetes research and clinical practice.
[11] M. Reni,et al. (Ir)relevance of Metformin Treatment in Patients with Metastatic Pancreatic Cancer: An Open-Label, Randomized Phase II Trial , 2015, Clinical Cancer Research.
[12] R. Riechelmann,et al. Phase II trial of metformin and paclitaxel for patients with gemcitabine-refractory advanced adenocarcinoma of the pancreas , 2015, Ecancermedicalscience.
[13] A. Zwinderman,et al. Metformin in patients with advanced pancreatic cancer: a double-blind, randomised, placebo-controlled phase 2 trial. , 2015, The Lancet. Oncology.
[14] R. Saskin,et al. Exploring the rising incidence of neuroendocrine tumors: A population‐based analysis of epidemiology, metastatic presentation, and outcomes , 2015, Cancer.
[15] P. Maisonneuve,et al. Diabetes, Smoking, Alcohol Use, and Family History of Cancer as Risk Factors for Pancreatic Neuroendocrine Tumors: A Systematic Review and Meta-Analysis , 2015, Neuroendocrinology.
[16] P. Ruszniewski,et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. , 2014, The New England journal of medicine.
[17] E. Gorak,et al. Metformin is associated with survival benefit in cancer patients with concurrent type 2 diabetes: a systematic review and meta-analysis. , 2013, The oncologist.
[18] M. Mete,et al. Treatment with metformin is associated with higher remission rate in diabetic patients with thyroid cancer. , 2013, The Journal of clinical endocrinology and metabolism.
[19] M. Kulke,et al. Targeted therapies in neuroendocrine tumors (NET): clinical trial challenges and lessons learned. , 2013, The oncologist.
[20] F. Berrino,et al. Targeting metabolism for cancer treatment and prevention: metformin, an old drug with multi-faceted effects , 2013, Oncogene.
[21] E. D. de Vries,et al. Everolimus for advanced pancreatic neuroendocrine tumors. , 2011, The New England journal of medicine.
[22] Y. Bang,et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. , 2011, The New England journal of medicine.
[23] P. O S I T I O N S T A T E M E N T,et al. Diagnosis and Classification of Diabetes Mellitus , 2011, Diabetes Care.
[24] I. Godsland. Insulin resistance and hyperinsulinaemia in the development and progression of cancer , 2009, Clinical science.
[25] R. Shaw,et al. The LKB1–AMPK pathway: metabolism and growth control in tumour suppression , 2009, Nature Reviews Cancer.
[26] V. Fendrich,et al. Surgical management of pancreatic endocrine tumors , 2009, Nature Reviews Clinical Oncology.
[27] P. Donnan,et al. New Users of Metformin Are at Low Risk of Incident Cancer , 2009, Diabetes Care.
[28] L. Cantley,et al. Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation , 2009, Science.
[29] G. Petersen,et al. Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.
[30] M. Bidlingmaier,et al. Effects of the long-acting somatostatin analogue Lanreotide Autogel on glucose tolerance and insulin resistance in acromegaly. , 2006, European journal of endocrinology.
[31] X. Ding,et al. Physiological Concentrations of Insulin Augment Pancreatic Cancer Cell Proliferation and Glucose Utilization By Activating MAP Kinase, PI3 Kinase and Enhancing GLUT-1 Expression , 2000, Pancreas.
[32] C. la Vecchia,et al. Risk factors for neuroendocrine neoplasms: a systematic review and meta-analysis. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.
[33] L. Schwartz,et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.